DUBLIN, October 6, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Autoimmune Partnering 2010-2016: Deal trends, players and financials" report to their offering.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
Global Autoimmune Partnering 2010 to 2016 provides
- Trends in Autoimmune partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Autoimmune partnering agreement structure
- Autoimmune partnering contract documents
- Top Autoimmune deals by value
- Most active Autoimmune dealmakers
The report includes coverage of the following autoimmune diseases:
- Multiple sclerosis
- Restless leg syndrome
- Eczema
- Alopecia
- Psoriasis
- Celiac disease
- Inflammatory bowel disease
- Crohn's disease
- Ulcerative colitis
- Glomerulonephritis
- Endometriosis
- Immune thrombocytopenic purpura
- Neutropenia
- Graft versus host disease
- Scleroderma
- Systemic lupus erythematosus
- Addison's disease
- Diabetes Type 1
- Ankylosing spondylitis
- Juvenile arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Uveitis
- Narcolepsy
- Idiopathic pulmonary fibrosis
- Sarcoidosis
- Meniere's disease
The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Autoimmune dealmaking
Chapter 3 - Financial deal terms for Autoimmune partnering
Chapter 4 - Leading Autoimmune deals and dealmakers
Chapter 5 - Autoimmune contract document directory
Chapter 6 - Autoimmune dealmaking by therapeutic target
For more information about this report visit http://www.researchandmarkets.com/research/szsl93/global_autoimmune
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
